Clovis Oncology, Inc. has received $-1.65 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 6 Financial Advisor in the Stock Trading Firms. Among 6 Analysts, Bottom line EPS Estimate for the current quarter is $-1.95 while the top line estimate is $-1.34 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 25.93%.
Clovis Oncology, Inc. reported better than expected with a surprise EPS of 10.05% or $0.19 during its most recent quarterly earnings. The Actual EPS was $-1.7 compared to the Estimated EPS of $-1.89.
In the last quarter, Clovis Oncology, Inc. reported Annual Earnings of $-1.7. Based on the filings, last years Annual Earnings was, $-8.85. In the last Quarter, CLVS reported a surprise Earnings per Share of 10.05% . The consensus estimate for current quarter is $-1.65 and for the current fiscal year, the estimate is $-7.4. For the Next fiscal year, the estimate is $-4.39 based on the consensus.
Clovis Oncology, Inc. (NASDAQ:CLVS) : On Tuesday heightened volatility was witnessed in Clovis Oncology, Inc. (NASDAQ:CLVS) which led to swings in the share price. The stock opened for trading at $61.61 and hit $64.9 on the upside , eventually ending the session at $64.8, with a gain of 4.8% or 2.97 points. The heightened volatility saw the trading volume jump to 2,311,855 shares. The 52-week high of the share price is $64.9 and the company has a market cap of $2,873 million. The 52-week low of the share price is at $11.57 .
Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations. Clovis Oncology Inc. is headquartered in Colorado, USA.